Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And...
Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And...
Evaxion生物科技已與默沙東簽訂了一項期權和許可協議，涉及兩個處於臨床前階段的疫苗候選者，預付款320萬美元，2025年最高可達1億美元，如果默沙東選擇行使其對其中一個或兩個候選者的許可權，
Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And Milestone Payments Of Up To $592M Per Product
Evaxion生物科技已與默沙東簽訂了一項期權和許可協議，涉及兩個臨床前生物-疫苗候選者，首付款爲320萬美元，2025年默沙東行使其許可期權時，可達到1000萬美元，每種產品的里程碑支付可高達59200萬美元
Under the terms of the agreement, Evaxion has granted MSD an option to exclusively license Evaxion's preclinical vaccine candidates EVX-B2 and EVX-B3. EVX-B2 is a protein-based candidate for Gonorrhea and EVX-B3 targets an undisclosed infectious agent.
根據協議條款，Evaxion已授予默克一個獨家許可期權，以獨家許可Evaxion的臨床前疫苗候選者EVX-B2和EVX-B3。 EVX-B2是一種基於蛋白質的淋病候選者，而EVX-B3針對一種未透露的傳染病原體。